Business Description
Akero Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US00973Y1082
Description
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 20.96 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.18 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -3.5 | |||||
3-Year EPS without NRI Growth Rate | -4.7 | |||||
3-Year FCF Growth Rate | -7 | |||||
3-Year Book Growth Rate | 8.8 | |||||
Future 3-5Y EPS without NRI Growth Rate | -10.7 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 56.85 | |||||
9-Day RSI | 53.26 | |||||
14-Day RSI | 52.27 | |||||
6-1 Month Momentum % | 12.43 | |||||
12-1 Month Momentum % | -43.01 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 24.89 | |||||
Quick Ratio | 24.89 | |||||
Cash Ratio | 24.39 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -17.1 | |||||
Shareholder Yield % | -19.31 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -30.21 | |||||
ROA % | -27.92 | |||||
ROIC % | -564.17 | |||||
ROC (Joel Greenblatt) % | -19513.45 | |||||
ROCE % | -28.38 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 2.38 | |||||
Price-to-Tangible-Book | 2.38 | |||||
EV-to-EBIT | -5.91 | |||||
EV-to-Forward-EBIT | -4.6 | |||||
EV-to-EBITDA | -5.91 | |||||
EV-to-Forward-EBITDA | -4.67 | |||||
EV-to-FCF | -6.19 | |||||
Price-to-Net-Current-Asset-Value | 2.68 | |||||
Price-to-Net-Cash | 2.74 | |||||
Earnings Yield (Greenblatt) % | -16.92 | |||||
FCF Yield % | -10.01 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Akero Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -3.18 | ||
Beta | -0.02 | ||
Volatility % | 110.65 | ||
14-Day RSI | 52.27 | ||
14-Day ATR (€) | 0.624013 | ||
20-Day SMA (€) | 23.0155 | ||
12-1 Month Momentum % | -43.01 | ||
52-Week Range (€) | 10.8 - 55 | ||
Shares Outstanding (Mil) | 69.43 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Akero Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Akero Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Akero Therapeutics Inc Frequently Asked Questions
What is Akero Therapeutics Inc(FRA:0K4)'s stock price today?
The current price of FRA:0K4 is €23.25. The 52 week high of FRA:0K4 is €55.00 and 52 week low is €10.80.
When is next earnings date of Akero Therapeutics Inc(FRA:0K4)?
The next earnings date of Akero Therapeutics Inc(FRA:0K4) is 2024-11-13 Est..
Does Akero Therapeutics Inc(FRA:0K4) pay dividends? If so, how much?
Akero Therapeutics Inc(FRA:0K4) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |